Xeris Biopharma Expects To Generate 2024 Revenue Of $203M, Exceeding Previous Guidance Of $198M-$202M Versus Consensus Of $199.70M, With Over $71M In Cash, Cash Equivalents, And Short-term Investments, Generating Positive Cash Flow In The Fourth Quarter

Benzinga

10 Jan

Other Fourth Quarter 2024 Updates

Recorlev achieved record number of new starts and referrals.
Gvoke ended the year with approximately 35% market share.
Keveyis maintained a similar number of patients on therapy as Q3 2024.
Beta Bionics, Inc.: Xeris successfully formulated a unique XeriSol formulation of glucagon for bi-hormonal pumps and pump systems. This triggered a milestone payment of $3 million in the fourth quarter.
Amgen: Amgen chose to terminate its exclusive worldwide license agreement with Xeris following a broader company portfolio assessment. Their decision was not related to the performance of the XeriJect formulation technology. The termination will not have a material impact on Xeris' outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2502857375"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502857375\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2502857375?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-10 20:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502857375","market":"hk","top_or_hot":-1,"title":"Xeris Biopharma Expects To Generate 2024 Revenue Of $203M, Exceeding Previous Guidance Of $198M-$202M Versus Consensus Of $199.70M, With Over $71M In Cash, Cash Equivalents, And Short-term Investments, Generating Positive Cash Flow In The Fourth Quarter","media":"Benzinga","content":"<html><body><p><strong>Other Fourth Quarter 2024 Updates</strong></p><ul><li><strong>Recorlev</strong> achieved record number of new starts and referrals.</li><li><strong>Gvoke</strong> ended the year with approximately 35% market share.</li><li><strong>Keveyis</strong> maintained a similar number of patients on therapy as Q3 2024.</li><li><strong>Beta Bionics, Inc.: </strong>Xeris successfully formulated a unique XeriSol formulation of glucagon for bi-hormonal pumps and pump systems. This triggered a milestone payment of $3 million in the fourth quarter.</li><li><strong>Amgen</strong>: Amgen chose to terminate its exclusive worldwide license agreement with Xeris following a broader company portfolio assessment. Their decision was not related to the performance of the XeriJect formulation technology. The termination will not have a material impact on Xeris' outlook.</li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xeris Biopharma Expects To Generate 2024 Revenue Of $203M, Exceeding Previous Guidance Of $198M-$202M Versus Consensus Of $199.70M, With Over $71M In Cash, Cash Equivalents, And Short-term Investments, Generating Positive Cash Flow In The Fourth Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXeris Biopharma Expects To Generate 2024 Revenue Of $203M, Exceeding Previous Guidance Of $198M-$202M Versus Consensus Of $199.70M, With Over $71M In Cash, Cash Equivalents, And Short-term Investments, Generating Positive Cash Flow In The Fourth Quarter\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-01-10 20:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Other Fourth Quarter 2024 Updates</strong></p><ul><li><strong>Recorlev</strong> achieved record number of new starts and referrals.</li><li><strong>Gvoke</strong> ended the year with approximately 35% market share.</li><li><strong>Keveyis</strong> maintained a similar number of patients on therapy as Q3 2024.</li><li><strong>Beta Bionics, Inc.: </strong>Xeris successfully formulated a unique XeriSol formulation of glucagon for bi-hormonal pumps and pump systems. This triggered a milestone payment of $3 million in the fourth quarter.</li><li><strong>Amgen</strong>: Amgen chose to terminate its exclusive worldwide license agreement with Xeris following a broader company portfolio assessment. Their decision was not related to the performance of the XeriJect formulation technology. The termination will not have a material impact on Xeris' outlook.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XERS","symbol_name":"Xeris制药","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/25/01/42909371/xeris-biopharma-expects-to-generate-2024-revenue-of-203m-exceeding-previous-guidance-of-198m-202m","article_id":"2502857375","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502857375","pubTimestamp":1736511459,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Other Fourth Quarter 2024 UpdatesRecorlev achieved record number of new starts and referrals.Gvoke ended the year with approximately 35% market share.Keveyis maintained a similar number of patients on therapy as Q3","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"XERS":"Xeris制药"},"translate_title":"Xeris Biopharma预计2024年收入为2.03亿美元，超过之前指导的1.98亿至2.02亿美元，而市场普遍预期为1.997亿美元，现金、现金等价物和短期投资超过7100万美元，在第四季度产生正现金流","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XERS":0.9},"content_text":"Other Fourth Quarter 2024 UpdatesRecorlev achieved record number of new starts and referrals.Gvoke ended the year with approximately 35% market share.Keveyis maintained a similar number of patients on therapy as Q3 2024.Beta Bionics, Inc.: Xeris successfully formulated a unique XeriSol formulation of glucagon for bi-hormonal pumps and pump systems. This triggered a milestone payment of $3 million in the fourth quarter.Amgen: Amgen chose to terminate its exclusive worldwide license agreement with Xeris following a broader company portfolio assessment. Their decision was not related to the performance of the XeriJect formulation technology. The termination will not have a material impact on Xeris' outlook.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}